Haleon PLC Sponsored ADR (HLN)
(Delayed Data from NYSE)
$8.84 USD
-0.08 (-0.90%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $8.84 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum C VGM
Haleon PLC Sponsored ADR (HLN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.78 | $10.10 | $9.45 | 9.64% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Haleon PLC Sponsored ADR comes to $9.78. The forecasts range from a low of $9.45 to a high of $10.10. The average price target represents an increase of 9.64% from the last closing price of $8.92.
Analyst Price Targets (2 )
Broker Rating
Haleon PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.81 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.81 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 61.54% and 7.69% of all recommendations. A month ago, Strong Buy made up 61.54%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.81 | 1.81 | 1.81 | 1.81 | 1.81 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Olivier Nicolai | Strong Buy | Strong Buy |
6/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/13/2024 | Not Identified | Not Identified | Hold | Hold |
6/5/2024 | Not Identified | Not Identified | Hold | Hold |
4/17/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/15/2024 | Argus Research Corp. | Taylor Conrad | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/1/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.81 |
ABR (Last week) | 1.81 |
# of Recs in ABR | 13 |
Average Target Price | $9.78 |
LT Growth Rate | 7.50% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 0.09 |